1. Lang K, Mosinger J, Wagnerová D. Photophysical properties of porphyrinoid sensitizers noncovalently
bound to host molecules; models for photodynamic therapy. Coordination chemistry reviews. 2004;248:321‐50.
2. Bonnett R, Martı́nez G. Photobleaching of sensitisers used in photodynamic therapy. Tetrahedron. 2001;57:9513‐47.
3. Andrade SM, Costa S. Spectroscopic studies on the interaction of a water soluble porphyrin and two drug carrier proteins. Biophys J.2002;82:1607‐19.
4. Berenbaum M, Akande S, Bonnett R, Kaur H, Ioannou S, White R, et al. Meso‐Tetra (hydroxyphenyl) porphyrins, a new class of potent tumour photosensitisers with favourable selectivity. Br J Cancer. 1986;54:717.
5. Lambrechts SA, Aalders MC, Verbraak FD, Lagerberg JW, Dankert JB, Schuitmaker JJ. Effect of albumin on the photodynamic inactivation of microorganisms by a cationic porphyrin. J Photochem Photobiol B. 2005;79:51‐7.
6. Gantchev TG, Ouellet R, van Lier JE. Binding interactions and conformational changes induced by sulfonated aluminum phthalocyanines in human serum albumin. Arch Biochem Biophys. 1999;366:21‐30.
7. An W, Jiao Y, Dong C, Yang C, Inoue Y, Shuang S.Spectroscopic and molecular modeling of the binding of meso‐tetrakis (4‐hydroxyphenyl) porphyrin to human serum albumin. Dyes and Pigments. 2009;81:1‐9.
8. Allison BA, Pritchard PH, Levy JG. Evidence for low‐density lipoprotein receptor‐mediated uptake of benzoporphyrin derivative. Br J Cancer. 1994; 69: 833–9.
9. Rovers J, Saarnak A, Molina A, Schuitmaker J, Sterenborg H, Terpstra O. Effective treatment of liver metastases with photodynamic therapy, using the second‐generation photosensitizer meta‐tetra (hydroxyphenyl) chlorin (mTHPC), in a rat model. Br J Cancer. 1999;81:600‐8.
10. Hambright P, Fawwaz R, Valk P, McRae J, Bearden A. The distribution of various water soluble radioactive metalloporphyrins in tumor bearing mice. Bioinorg Chem. 1975;5:87‐92.
11. Whelan HT, Kras LH, Ozker K, Bajic D, Schmidt MH, Liu Y, et al. Selective incorporation f111Inlabeled
PHOTOFRIN™ by glioma tissuein vivo. J Neurooncol. 1994;22:7‐13.
12. Bhalgat MK, Roberts JC, Mercer‐Smith JA, Knotts BD, Vessella RL, Lavallee DK. Preparation and biodistribution of copper‐67‐labeled porphyrins and porphyrin‐A6H immunoconjugates. Nucl Med Biol. 1997; 24:179‐85.
13. Subbarayan M, Shetty S, Srivastava T, Noronha O, Samuel A. Evaluation studies of technetium‐99mporphyrin (T3, 4BCPP) for tumor imaging. J Porphyrins Phthalocyanines. 2001;5:824‐8.
14. Kavali RR, Chul Lee B, Seok Moon B, Dae Yang S, Soo Chun K, Woon Choi C, et al. Efficient methods for the synthesis of 5‐(4‐[18F] fluorophenyl)‐10, 15, 20‐tris (3‐methoxyphenyl) porphyrin as a potential imaging agent for tumor. J Label Compd Radiopharm. 2005;48:749‐58.
15. Das T, Chakraborty S, Sarma H, Banerjee S. A novel [109Pd] palladium labeled porphyrin for possible use in targeted radiotherapy. Radiochimica Acta. 2008;96:427‐33.
16. Yamazaki K, Hirata S, Nakajima S, Kubo Y, Samejima N, Sakata I. Whole‐body Autoradiography of Tumor‐bearing Hamsters with a New Tumor Imaging Agent, Indium‐111‐labeled Porphyrin. Jpn J Cancer Res. 1988;79:880‐4.
17. Quastel M, Richter A, Levy J. Tumour scanning with indium‐111 dihaematoporphyrin ether. Br J
Cancer. 1990;62:885.
18. Sadeghpour H, Jalilian AR, Akhlaghi M, Kamalidehghan M, Mirzaii M. Preparation and Biodistribution of [111In]‐rHuEpo for
Erythropoietin Receptor Imaging. J Radioanal Nucl Chem. 2008; 278:117‐122.
19. Mirzaii M, Afarideh H, Haji‐Saied SM, Ardaneh K.Production of 111 In by irradiation of natural cadmium with deuterons and protons in NRCAM cyclotron. Energy (MeV). 1998; 6: 16.
20. Sangster J. Octanol‐water partition coefficients of simple organic compounds. Washington DC:
American Chemical Society and the American Institute of Physics for the National Institute of
Standards and Technology; 1989.
21. United States Pharmacopoeia 28, 2005, NF 23,p.1009.
22. United States Pharmacopoeia 28, 2005, NF 23,p.1895.
23. Bernard C. Chemistry of Metal Radionuclides (Rb,Ga, In, Y, Cu and Tc)
)